Silo Pharma, Inc. (SILO) 股票分析

公司概述

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company dedicated to creating therapeutics for underserved medical conditions, specifically targeting post-traumatic stress disorder, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to address niche therapeutic areas with high unmet medical needs. As of the latest data, Silo Pharma maintains a market capitalization of $7.19 million, generates annual revenue of $72,102, and employs a workforce of 3 individuals. These financial metrics indicate that the company is a micro-cap entity with minimal revenue generation relative to its valuation, reflecting its status as a pre-revenue or early-stage enterprise where value is derived primarily from pipeline potential rather than current sales performance. The extremely low revenue figure combined with a small employee count underscores the resource-intensive nature of drug development, where significant capital is typically required to advance clinical candidates before any substantial commercial return is realized.

财务健康

The company reported revenue of $72,102 for the trailing twelve months, yet recorded a net income loss of $4,227,698 and an EBITDA of $4,269,222. The substantial gap between the negligible revenue and the multi-million dollar net loss reveals a cost structure dominated by heavy research and development expenditures, which is characteristic of developmental stage biopharmaceutical firms but highlights significant operational burn rates. Free cash flow stands at $-3,555,834, indicating that the company is currently burning cash to fund operations and development efforts rather than generating liquidity from its core activities. This negative cash flow position limits immediate financial flexibility, necessitating reliance on existing cash reserves or external financing to sustain ongoing R&D programs. The company exhibits a gross margin of 38.6%, while the operating margin is an extreme -4363.3% and profit margin is 0.0%, reflecting that operating expenses vastly exceed gross profits due to the high costs of development without corresponding commercial scale. Despite these losses, Silo Pharma holds cash reserves of $6.86 million against zero debt, creating a distinct imbalance where liquidity is present but earnings are negative. The current ratio is an exceptionally high 11.36, indicating that short-term assets significantly outweigh short-term liabilities, suggesting a robust liquidity position on a balance sheet that carries no leverage. Return on Equity is -74.6% and Return on Assets is -35.6%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the absence of profitable operations.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, whereas the forward P/E is recorded as -0.63, implying that the market expects the company to remain unprofitable in the near term. The price-to-book ratio is 0.93, suggesting that the market values the company at 93% of its book value, which often occurs when investors discount assets that are not yet generating cash flows or when the book value does not fully reflect the intangible value of the drug pipeline. The price-to-sales ratio is 99.72, an extremely high multiple that indicates the market is pricing the stock based on future expectations of commercial success rather than current earnings, while the EV/EBITDA stands at 0.14, further emphasizing the disconnect between current operational cash generation and market valuation. The 52-week high is $1.19 and the 52-week low is $0.22, meaning the current trading price sits significantly below the yearly peak, reflecting the high volatility typical of small-cap biotech stocks. With a beta of 0.59, the stock exhibits lower volatility relative to the broader market, moving less sharply than the overall index, which provides a relative stability metric despite the underlying business risks associated with drug development.

Growth & Income

Revenue growth year-over-year is 0.0%, and earnings growth is N/A, indicating that the company has not yet achieved positive earnings or demonstrated top-line expansion in the recent period. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning all available cash resources are theoretically available for reinvestment into research and development or to cover operational losses rather than being distributed to shareholders. The absence of dividends confirms the company's strategy of retaining capital to fund its pipeline, although the current negative cash flow suggests that external capital raising may be necessary to sustain this approach. Overall, Silo Pharma presents a growth profile defined by high risk and low current financial returns, with no income generation from dividends or earnings to support shareholder wealth in the short term.